MIM
IOVA icon

MetLife Investment Management’s Iovance Biotherapeutics IOVA Stock Holding History

MetLife Investment Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$966K Buy
232,151
+47,752
+26% +$181K ﹤0.01% 1545
2026
Q1 		$647K Buy
184,399
+13,617
+8% +$43.6K ﹤0.01% 1628
2025
Q4 		$466K Buy
170,782
+29,096
+21% +$67.3K ﹤0.01% 1821
2025
Q3 		$307K Sell
141,686
-9,288
-6% -$21.9K ﹤0.01% 2069
2025
Q2 		$260K Sell
150,974
-232
-0.2% -$577 ﹤0.01% 2041
2025
Q1 		$504K Sell
151,206
-14,636
-9% -$75.5K ﹤0.01% 1726
2024
Q4 		$1.23M Buy
165,842
+19,426
+13% +$180K 0.01% 1312
2024
Q3 		$1.37M Hold
146,416
– – 0.01% 1210
2024
Q2 		$1.17M Buy
146,416
+25,310
+21% +$271K 0.01% 1260
2024
Q1 		$1.79M Hold
121,106
– – 0.01% 1000
2023
Q4 		$985K Hold
121,106
– – 0.01% 1301
2023
Q3 		$551K Buy
121,106
+11,390
+10% +$74.4K ﹤0.01% 1574
2023
Q2 		$772K Buy
109,716
+31,145
+40% +$223K 0.01% 1420
2023
Q1 		$480K Hold
78,571
– – ﹤0.01% 1673
2022
Q4 		$502K Hold
78,571
– – ﹤0.01% 1644
2022
Q3 		$753K Hold
78,571
– – 0.01% 1344
2022
Q2 		$867K Buy
78,571
+73,566
+1,470% +$964K 0.01% 1286
2022
Q1 		$83.3K Buy
+5,005
New +$77.4K ﹤0.01% 2645
2020
Q2 		– Sell
-49,133
Closed -$1.47M – 2325
2020
Q1 		$1.47M Sell
49,133
-2,460
-5% -$65.2K 0.02% 738
2019
Q4 		$1.43M Hold
51,593
– – 0.01% 939
2019
Q3 		$939K Buy
51,593
+3,281
+7% +$72.6K 0.01% 1102
2019
Q2 		$1.18M Sell
48,312
-96,624
-67% -$1.46M 0.01% 1029
2019
Q1 		$1.38M Buy
144,936
+96,624
+200% +$939K ﹤0.01% 1474
2018
Q4 		$428K Buy
48,312
+9,549
+25% +$92.1K 0.01% 1461
2018
Q3 		$436K Buy
+38,763
New +$550K ﹤0.01% 1616

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

MetLife Investment Management's IOVA Position: Q2 2026 in Review

MetLife Investment Management increased its Iovance Biotherapeutics (IOVA) stake by 26% in Q2 2026, buying an estimated $181K and bringing the position to 232,151 shares worth $966K. The position accounts for ﹤0.01% of the portfolio, ranked #1545.

MetLife Investment Management first reported a position in IOVA in Q3 2018 and has held it in 25 quarters since. The position peaked at $1.79M in Q1 2024. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • MetLife Investment Management held 232,151 shares of Iovance Biotherapeutics worth $966K as of Q2 2026.
  • MetLife Investment Management bought 47,752 Iovance Biotherapeutics shares in Q2 2026, an estimated $181K.
  • Iovance Biotherapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #1545 holding.
  • MetLife Investment Management first reported a position in Iovance Biotherapeutics in Q3 2018 and has held it in 25 quarters since.
  • MetLife Investment Management's Iovance Biotherapeutics position peaked at $1.79M in Q1 2024.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.